Advertisement

Journal of Neurology

, Volume 256, Issue 7, pp 1095–1102 | Cite as

The effects of l-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial

  • Sarah A. Morrow
  • Tanya Kaushik
  • Peter Zarevics
  • David Erlanger
  • Mark F. Bear
  • Frederick E. Munschauer
  • Ralph H. B. BenedictEmail author
Original Communication

Abstract

Defects in processing speed and memory are common in multiple sclerosis (MS) patients. In other populations, amphetamines have been shown to enhance cognition, but their use is limited by adverse behavioral effects. The l-isomer may have equivalent cognition enhancement with less adverse effects due to decreased potency in subcortical areas. The aim of this study was to assess the safety and efficacy of l-amphetamine sulfate in the treatment of cognitive dysfunction in MS. This was a 2:1 randomized, placebo-controlled, double-blind trial, involving 33 MS clinics across the USA. One hundred and fifty-one clinically definite MS patients with documented cognitive dysfunction who were relapse free for ≥90 days, with an Expanded Disability Status Scale (EDSS) ≤6.5, and with no other medical/psychiatric condition that may cause psychological dysfunction were randomized to 30 mg of oral l-amphetamine sulfate or placebo for 29 days, including a dose escalation period. A history of cardiac disease, uncontrolled hypertension or electrocardiograph abnormalities resulted in exclusion. The primary outcomes were the Subject Global Assessment of Change and Symbol Digit Modalities Test (SDMT). Secondary outcomes were the results from the California Verbal Learning Test, second edition (CVLT2), Brief Visual Memory Test-Revised (BVMTR), and Paced Auditory Serial Addition Test (PASAT). One hundred and thirty-six subjects completed the study. No differences were found at baseline in demographics or in the results of the neuropsychological tests. After treatment, the active group performed significantly better for total learning (P = 0.041) and delayed recall (P < 0.01) on the BVMTR, and for delayed recall (P = 0.012) on the CVLT2. Five patients (four from the treatment group, one placebo) withdrew due to intolerable adverse events. l-amphetamine sulfate was associated with improved learning and memory and was well tolerated in this study. However, because the positive findings were observed on secondary outcome measures, the study requires replication before l-amphetamine sulfate can be recommended for the treatment of cognitive impairment in MS.

Keywords

Adverse events Amphetamines l-amphetamine sulfate Cognition enhancement Cognitive impairment Multiple sclerosis 

Notes

Acknowledgments

This trial was sponsored by Cognition Pharmaceuticals, LLC. The authors would like to acknowledge the primary investigators at each participating site: R. Aung-din, Sarasota FL, J. Berger, Lexington KY, M. Cascione, Tampa FL, S. Elias, Detroit MI, B. Evans Traverse City MI, C. Ford, Albuquerque NM, E. Fox, Round Rock TX, S.M. Freedman, Raleigh NC, S. Gazda San Antonio TX, D. Giang, Loma Linda CA, D. Greco Danbury CT, J. Gross, Fairfield CT, W. Honeycutt, Maitland FL, G. Hutton, Houston, TX, A. Keegan, Sarasota FL, K. Kresa-Reahl, Charleston WV, T. Leist, Philadelphia PA, S. Lynch, Kansas City KS, A. Mazhari, Akron OH, F. Munchauer, Buffalo NY, J. Preiningerova New Haven CT, S. Rizvi, Providence RI, V. Rowe, Lenexa CT, S. Scarberry, Fargo ND, M. Shcmerler, Cinncinnati OH, J. Shi, Charlottesville VA, H. Sullivan, Grand Rapids MI, C. Thiagarajah, Lancaster CA, B. Thrower Atlanta GA, S. Thurston, Richmond VA, A. Vasquez, St. Petersburg FL, J. Wendt, Tuscon AZ.

Conflict of interest statement

Dr. Morrow has no conflict of interest or financial disclosures related to this project.

Dr. Kaushik supervised the trial on behalf of the sponsor company.

Mr. Zarevics served as consultant for trial design and management on behalf of the sponsor company.

Dr. Erlanger has financial interest in the sponsor company.

Dr. Bear has no conflict of interest or financial disclosures related to this project.

Dr. Munschauer has no conflict of interest or financial disclosures related to this project.

Dr. Benedict received financial support from Cognition Pharmaceuticals LLC, to support his role as PI in this study.

This trial was registered with ClinTrials.gov

References

  1. 1.
    Rao SM (1995) Neuropsychology of multiple sclerosis. Curr Opin Neurol 8:216–220. doi: 10.1097/00019052-199506000-00010 PubMedCrossRefGoogle Scholar
  2. 2.
    Bobholz JA, Rao SM (2003) Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 16:283–288. doi: 10.1097/00019052-200306000-00006 PubMedCrossRefGoogle Scholar
  3. 3.
    Goodin DS, Frohman EM, Garmany GP Jr et al (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169–178PubMedGoogle Scholar
  4. 4.
    Lee EH, Ma YL (1995) Amphetamine enhances memory retention and facilitates norepinephrine release from the hippocampus in rats. Brain Res Bull 37:411–416. doi: 10.1016/0361-9230(95)00039-9 PubMedCrossRefGoogle Scholar
  5. 5.
    Brown RW, Bardo MT, Mace DD, Phillips SB, Kraemer PJ (2000) D-amphetamine facilitation of morris water task performance is blocked by eticlopride and correlated with increased dopamine synthesis in the prefrontal cortex. Behav Brain Res 114:135–143. doi: 10.1016/S0166-4328(00)00225-4 PubMedCrossRefGoogle Scholar
  6. 6.
    Barch DM (2006) What can research on schizophrenia tell us about the cognitive neuroscience of working memory? Neuroscience 139:73–84. doi: 10.1016/j.neuroscience.2005.09.013 PubMedCrossRefGoogle Scholar
  7. 7.
    Wright FK, White KG (2003) Effects of methylphenidate on working memory in pigeons. Cogn Affect Behav Neurosci 3:300–308. doi: 10.3758/CABN.3.4.300 PubMedCrossRefGoogle Scholar
  8. 8.
    Mattay VS, Callicott JH, Bertolino A et al (2000) Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 12:268–275. doi: 10.1006/nimg.2000.0610 PubMedCrossRefGoogle Scholar
  9. 9.
    Mason ST (1983) The neurochemistry and pharmacology of extinction behavior. Neurosci Biobehav Rev 7:325–347. doi: 10.1016/0149-7634(83)90036-2 PubMedCrossRefGoogle Scholar
  10. 10.
    Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40:191–225. doi: 10.1146/annurev.ps.40.020189.001203 PubMedCrossRefGoogle Scholar
  11. 11.
    Engber TM, Dennis SA, Jones BE, Miller MS, Contreras PC (1998) Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neuroscience 87:905–911. doi: 10.1016/S0306-4522(98)00015-3 PubMedCrossRefGoogle Scholar
  12. 12.
    Kuczenski R, Segal DS, Cho AK, Melega W (1995) Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15:1308–1317PubMedGoogle Scholar
  13. 13.
    Benedict RH, Munschauer F, Zarevics P et al (2008) Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. J Neurol 255:848–852. doi: 10.1007/s00415-008-0760-7 PubMedCrossRefGoogle Scholar
  14. 14.
    Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846. doi: 10.1002/ana.20703 PubMedCrossRefGoogle Scholar
  15. 15.
    Rao SM (1991) A manual for the brief, repeatable battery of neuropsychological tests in multiple sclerosis. Cognitive Function Study Group, National Multiple Schlerosis Society, PortlandGoogle Scholar
  16. 16.
    Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California verbal learning test: adult version. Psychological Corporation, San AntonioGoogle Scholar
  17. 17.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Ann Neurol 13:227–231. doi: 10.1002/ana.410130302 CrossRefGoogle Scholar
  18. 18.
    Wilkinson JE (ed) (1993) Wide range achievement test administration manual: 1993 edition. Wide Range, Inc., WilmingtonGoogle Scholar
  19. 19.
    Schneider LS, Olin JT (1996) Clinical global impressions in Alzheimer’s clinical trials. Int Psychogeriatr 8:277–288. doi: 10.1017/S1041610296002645 discussion 288–290PubMedCrossRefGoogle Scholar
  20. 20.
    Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE (2004) Donepezil improves memory in multiple sclerosis in a randomized clinical trial. Neurology 63:1579–1585PubMedGoogle Scholar
  21. 21.
    Benedict RH, Duquin JA, Jurgensen S et al (2008) Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 14:940–946. doi: 10.1177/1352458508090923 PubMedCrossRefGoogle Scholar
  22. 22.
    Benedict RHB (2005) Effects of using same vs. alternate form memory tests in short-interval, repeated assessment in multiple sclerosis. J Int Neuropsychol Soc 11:727–736. doi: 10.1017/S1355617705050782 PubMedCrossRefGoogle Scholar
  23. 23.
    Fischer JS, Rudick RA, Cutter GR, Reingold SC (1999) The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 5:244–250PubMedGoogle Scholar
  24. 24.
    Benedict RHB, Fischer JS, Archibald CJ et al (2002) Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 16:381–397. doi: 10.1076/clin.16.3.381.13859 PubMedGoogle Scholar
  25. 25.
    Benedict RH, Cookfair D, Gavett R et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 12:549–558. doi: 10.1017/S1355617706060723 PubMedCrossRefGoogle Scholar
  26. 26.
    Rhodes SM, Coghill DR, Matthews K (2004) Methylphenidate restores visual memory, but not working memory function in attention deficit-hyperkinetic disorder. Psychopharmacology (Berl) 175:319–330. doi: 10.1007/s00213-004-1833-7 CrossRefGoogle Scholar
  27. 27.
    Bedard AC, Martinussen R, Ickowicz A, Tannock R (2004) Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43:260–268. doi: 10.1097/00004583-200403000-00006 PubMedCrossRefGoogle Scholar
  28. 28.
    Barch DM, Carter CS (2005) Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 77:43–58. doi: 10.1016/j.schres.2004.12.019 PubMedCrossRefGoogle Scholar
  29. 29.
    Kim YH, Ko MH, Na SY, Park SH, Kim KW (2006) Effects of single-dose methylphenidate on cognitive performance in patients with traumatic brain injury: a double-blind placebo-controlled study. Clin Rehabil 20:24–30. doi: 10.1191/0269215506cr927oa PubMedCrossRefGoogle Scholar
  30. 30.
    Bear MF (1997) How do memories leave their mark? Nature 385:481–482. doi: 10.1038/385481a0 PubMedCrossRefGoogle Scholar
  31. 31.
    Heikkila RE, Orlansky H, Mytilineou C, Cohen G (1975) Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194:47–56PubMedGoogle Scholar
  32. 32.
    Wiig KAWJ, Epstein MH, Carpenter RL, Bear MF (2009) The levo enantiomer of amphetamine increases memory consolidation and gene expression in the hippocampus without producing locomotor stimulation. Neurobiol Mem Learn (in press)Google Scholar
  33. 33.
    Izquierdo I, Medina JH (1997) Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol Learn Mem 68:285–316. doi: 10.1006/nlme.1997.3799 PubMedCrossRefGoogle Scholar
  34. 34.
    Taubenfeld SM, Wiig KA, Monti B, Dolan B, Pollonini G, Alberini CM (2001) Fornix-dependent induction of hippocampal CCAAT enhancer-binding protein [beta] and [delta] Co-localizes with phosphorylated cAMP response element-binding protein and accompanies long-term memory consolidation. J Neurosci 21:84–91PubMedGoogle Scholar
  35. 35.
    Ridley RM, Maclean CJ, Young FM, Baker HF (2002) Learning impairments in monkeys with combined but not separate excitotoxic lesions of the anterior and mediodorsal thalamic nuclei. Brain Res 950:39–51. doi: 10.1016/S0006-8993(02)02984-0 PubMedCrossRefGoogle Scholar
  36. 36.
    Warburton EC, Baird AL, Morgan A, Muir JL, Aggleton JP (2000) Disconnecting hippocampal projections to the anterior thalamus produces deficits on tests of spatial memory in rats. Eur J Neurosci 12:1714–1726. doi: 10.1046/j.1460-9568.2000.00039.x PubMedCrossRefGoogle Scholar
  37. 37.
    Segal M, Markram H, Richter-Levin G (1991) Actions of norepinephrine in the rat hippocampus. Prog Brain Res 88:323–330. doi: 10.1016/S0079-6123(08)63819-4 PubMedCrossRefGoogle Scholar
  38. 38.
    Murchison CF, Zhang XY, Zhang WP, Ouyang M, Lee A, Thomas SA (2004) A distinct role for norepinephrine in memory retrieval. Cell 117:131–143. doi: 10.1016/S0092-8674(04)00259-4 PubMedCrossRefGoogle Scholar
  39. 39.
    Jurgens CW, Rau KE, Knudson CA et al (2005) Beta1 adrenergic receptor-mediated enhancement of hippocampal CA3 network activity. J Pharmacol Exp Ther 314:552–560. doi: 10.1124/jpet.105.085332 PubMedCrossRefGoogle Scholar
  40. 40.
    Lovera J, Bagert B, Smoot K et al (2007) Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler 13:376–385PubMedGoogle Scholar
  41. 41.
    Fischer JS, Priore RL, Jacobs LD et al (2000) Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 48:885–892. doi: 10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1 PubMedCrossRefGoogle Scholar
  42. 42.
    Fisher E, Rudick RA, Cutter G et al (2000) Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 6:373–377PubMedGoogle Scholar
  43. 43.
    Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N (2008) Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci 35:476–481PubMedGoogle Scholar
  44. 44.
    Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB (1996) The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 53:185–188PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Sarah A. Morrow
    • 1
  • Tanya Kaushik
    • 2
  • Peter Zarevics
    • 3
  • David Erlanger
    • 4
  • Mark F. Bear
    • 5
  • Frederick E. Munschauer
    • 1
  • Ralph H. B. Benedict
    • 1
    Email author
  1. 1.Jacobs Neurological InstituteState University of New York at BuffaloBuffaloUSA
  2. 2.Clinical Affairs PanMedix Inc.New YorkUSA
  3. 3.Clinical Operations Seaside TherapeuticsPhiladelphiaUSA
  4. 4.Cognition Pharmaceuticals, LLCNew YorkUSA
  5. 5.Massachusetts Institute of Technology (MIT), Department of Brain and Cognitive Sciences InvestigatorHoward Hughes Medical InstituteCambridgeUSA

Personalised recommendations